高敏肌钙蛋白T与择期PCI术后死亡率
本研究纳入5626例择期PCI患者,按基线与术后高敏肌钙蛋白T(hs-TnT)水平分四组,分析3年死亡率。校正后基线hs-TnT水平与死亡率增加相关,而术后峰值hs-TnT与死亡率无关。结论:择期PCI术后hs-TnT升高不提供超出基线水平的预后信息。
要点
- 基线hs-TnT升高者3年死亡率明显高于基线正常者。
- 术后hs-TnT峰值升高与死亡率无独立关联。
- 择期PCI后常规检测hs-TnT的预后价值有限。
核心结论
- 择期PCI术后hs-TnT升高不提供超出基线hs-TnT水平的预后信息。
研究设计与样本
- 纳入5626例接受择期PCI且具备基线与术后峰值hs-TnT测量值的患者,按基线及术后hs-TnT水平分为四组,主要结局为3年死亡率。
主要发现
- 共发生265例死亡:基线与术后均不升高组6例(1.6%),基线不升高但术后升高组54例(3.8%),基线升高术后无进一步升高组50例(16.0%),基线升高且术后进一步升高组155例(18.2%)(p < 0.001)。
- 校正后基线hs-TnT水平与死亡率增加相关(HR:1.22;95%CI:1.09-1.38;p < 0.001),而术后峰值hs-TnT无显著关联(HR:1.04;95%CI:0.85-1.28;p = 0.679)。
- 术后峰值hs-TnT在基线不升高组(HR:0.93;95%CI:0.69-1.25;p = 0.653)和基线升高组(HR:1.24;95%CI:0.91-1.69;p = 0.165)中均与死亡率无关。
临床怎么用
- 择期PCI术后hs-TnT升高应结合基线水平解读,不应单独用于预后分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognostic value of high-sensitivity troponin T (hs-TnT) elevation after elective percutaneous coronary intervention (PCI) in patients with or without raised baseline hs-TnT levels is unclear. OBJECTIVES: The goal of this study was to assess whether the prognostic value of post-procedural hs-TnT level after elective PCI depends on the baseline hs-TnT level. METHODS: This study included 5,626 patients undergoing elective PCI who had baseline and peak post-procedural hs-TnT measurements available. The primary outcome was 3-year mortality (with risk estimates calculated per SD increase of the log hs-TnT scale). RESULTS: Patients were divided into 4 groups: nonelevated baseline and post-procedural hs-TnT levels (hs-TnT ≤0.014 μg/l; n = 742); nonelevated baseline but elevated post-procedural hs-TnT levels (peak post-procedural hs-TnT >0.014 μg/l; n = 2,721); elevated baseline hs-TnT levels (hs-TnT >0.014 μg/l) with no further rise post-procedure (n = 516); and elevated baseline hs-TnT levels with a further rise post-procedure (n = 1,647). A total of 265 deaths occurred: 6 (1.6%) in patients with nonelevated baseline and post-procedural hs-TnT levels; 54 (3.8%) in patients with nonelevated baseline but elevated post-procedural hs-TnT levels; 50 (16.0%) in patients with elevated baseline hs-TnT levels with no further rise post-procedure; and 155 (18.2%) in patients with elevated baseline hs-TnT levels with a further rise post-procedure (p < 0.001). After adjustment, baseline hs-TnT levels (hazard ratio [HR]: 1.22; 95% confidence interval [CI]: 1.09 to 1.38; p < 0.001) but not peak post-procedural hs-TnT levels (HR: 1.04; 95% CI: 0.85 to 1.28; p = 0.679) were associated with an increased risk of mortality. Peak post-procedural hs-TnT findings were not associated with mortality in patients with nonelevated (HR: 0.93; 95% CI: 0.69 to 1.25; p = 0.653) or elevated (HR: 1.24; 95% CI: 0.91 to 1.69; p = 0.165) baseline hs-TnT levels. CONCLUSIONS: In patients with coronary artery disease undergoing elective PCI, an increase in post-procedural hs-TnT level did not offer prognostic information beyond that provided by the baseline level of the biomarker.
引用
- Ndrepepa G, Colleran R, Braun S, et al. High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention. J Am Coll Cardiol. 2016. PMID: 27884243. doi:10.1016/j.jacc.2016.08.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。